Symptomatic Irreversible Pulpitis With Apical Peridontitis
Conditions
Keywords
Gingival crevicular fluid, Matrix Metalloproteinase 9, Neurokinin A
Brief summary
The aim of this study is to investigate the levels Neurokinin A and of Matrix Mtalloproteinase (MMP-9) in gingival crevicular fluid samples (GCF) as potential biomarkers for the diagnosis of symptomatic irreversible pulpitis with symptomatic apical periodontitis and to correlate the level of these diagnostic biomarkers ( Nerokinin A and MMP-9) with the pre-operative pain severity using the Numerical Rating Scale (NRS). This study will utilize a comparative cross-sectional design to assess the levels of Neurokinin A (NKA) and Matrix metalloproteinase-9 (MMP-9) in gingival crevicular fluid (GCF) samples from symptomatic and healthy contralateral teeth with normal pulp.
Detailed description
The study design is Comparative Cross sectional study. The study will be conducted at the Dental hospital of Cairo University with access to patients undergoing treatment for teeth with pulpitis and apical periodontitis.
Interventions
DIAGNOSTIC_TESTGingival crevicular fluid samples from the symptomatic teeth and the healthy contrlateral teeth
The detection of the inflammatory biomarkers levels in the gingival crevicular fluid of the symptomatic teeth is considered an objective,molecular-based and non invasive method for diagnosis.
Sponsors
Hadeer Mostafa El Mohamady El Feky
Study design
Observational model
OTHER
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
* Adults (aged 18-60) diagnosed with symptomatic irreversible pulpitis with symptomatic apical periodontitis and have healthy contralateral teeth with normal pulp. * The involved teeth should have healthy periodontal conditions (Normal periodontal pocket depth, No bleeding on Probing and No mobility). * Patients who have not undergone any previous dental treatments in the involved teeth. * Signed informed consent.
Exclusion criteria
* Patients with systemic diseases affecting the immune response (e.g., autoimmune diseases, uncontrolled diabetes). * Patients taking medications that can affect the inflammatory markers (e.g., Steroids and Tetracyclins). * Smokers. * Individuals with periodontal disease unrelated to apical periodontitis. * Presence of marginal bone loss. * Pregnant women.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| The level of Neurokinin A in gingival crevicular fluid samples of teeth diagnosed with symptomatic irreversible pulpitis with symptomatic apical peridontitis and the contralateral teeth with healthy normal pulp. | Pre-operative measurement for Neurokinin A in gingival crevicular fluid samples | Method of Measurement: Human Neurokinin A ELISA Kit (Bioassay Technology Laboratory, Shanghai, China) - Unit of measurement: Pg/ml |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| A- The level of MMP-9 in gingival crevicular fluid samples of the symptomatic teeth and the contralateral teeth with normal pulp. B- The pre-operative pain severity in relation with the levels of these diagnostic biomarkers (Nerokinin A and MMP-9). | A- Pre-operative measurement for Matrix Metalloproteinase 9 in gingival crevicular fluid samples. B- Pre-operative pain severity assessment to corelate it with the levels of these diagnostic biomarkers (Nerokinin A and MMP-9).. | Methods of measurement: A- Human Matrix Metalloproteinase 9;Gelatinase B- ELISA Kit: (Bioassay Technology Laboratory, Shanghai, China) - Unit of measurement: Pg/ml B- The Numerical Rating Scale (NRS): is a commonly used tool for assessing pain severity and consists of a line (either vertical or horizontal) divided into 11 numbers ranging from 0 to 10, where 0 represents no pain and 10 represents the worst possible pain - Unit of measurement: Score (0-10) |
Countries
Egypt
Contacts
Primary ContactHadeer M El Mohamady El Feky, BDS, MSc, PhD Candidate
Outcome results
None listed